Chris O'Brien Lifehouse Hospital

Camperdown, New South Wales 2050

2 studies enrolling now · 7 studies all time

What they study most

Advanced Cholangiocarcinoma, Advanced Malignant Neoplasm, Advanced Solid Tumor, Breast Cancer, Colorectal Cancer, ER/PR Positive Breast Cancer, ER/PR(+), Her2(-) Breast Cancer, Endometrial Cancer, FGFR2 Gene Mutation, Gall Bladder Cancer, HER2+ Breast Cancer, HER2- Breast Cancer

Studies at this site

• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• First-in-Human Study of TAK-280 in Participants With Solid Tumors — Stopped early
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
• A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed